Introduction
Although > 95% of testicular germ-cell tumors are curable when appropriately treated, pure testicular choriocarcinoma carries a poor prognosis, with a 5-year survival of < 80% in the United States. 1 This testicular cancer variant often presents with high levels of serum b human chorionic gonadotropin (b-hCG) and widespread metastases with rapid disease progression. 2 To achieve a cure, bhCG levels must become undetectable. Persisting b-hCG levels, even after clinical evidence of disease resolution, reflect residual tumor and eventual relapse. 2, 3 Primary male choriocarcinoma of the upper urinary tract is an extremely rare malignancy, with fewer than 10 cases reported in the literature. [4] [5] [6] [7] [8] [9] [10] [11] Many of these tumors are thought to arise from trophoblastic (choriocarcinomatous) differentiation of high-grade urothelial carcinoma. 4, [7] [8] [9] [10] Herein we describe a man with choriocarcinoma of the renal pelvis, likely of urothelial origin, who was successfully treated with nephrectomy followed by multiple sequential chemotherapy regimens.
Case Report
A 48-year-old Hispanic man developed left-sided flank pain and gross hematuria in summer 2013. The patient had never smoked, occasionally drank alcohol, and did not abuse recreational drugs. He had served in the military from 1984 to 1994, and at the time of presentation, he worked in information technology support. His family history included a maternal grandfather with gastric cancer and an aunt with breast cancer.
At examination, chest, lung, abdominal, and scrotal examinations revealed nothing abnormal. Computed tomographic (CT) imaging revealed a left kidney mass and multiple bilateral lung nodules consistent with metastatic disease. On July 8, 2013, the patient underwent left nephroureterectomy. Pathology revealed a choriocarcinoma 9.5 cm in greatest dimension. The multinucleated syncytiotrophoblasts ( Figure 1 ) demonstrated positive immunohistochemical staining for b-hCG, SALL-4, GATA-3, PIN dual, and inhibin, as well as negative staining for cytokeratin 20, RCC, PAX-8, p63, OCT-3/4, thrombomodulin, and glypican-3. The
Clinical Practice Points
The clinical presentation of male choriocarcinomas of the upper urinary tract is often similar to renal-cell carcinoma and may include flank pain, macrohematuria, and a large kidney mass with pulmonary metastases. Diagnosis is frequently established after nephroureterectomy, which may complicate cisplatin-based chemotherapy regimens.
To achieve a cure, serum b human chorionic gonadotropin levels must become undetectable.
We describe the first case of a man with a choriocarcinomatous tumor of the renal pelvis and metastases to the lungs who experienced complete remission for almost 3 years to date after sequential Adriamycin, paclitaxel, and cisplatin (ATP) Â 3 doses, gemcitabine, paclitaxel, and Adriamycin (GTA) Â 3 doses, standard bleomycin, etoposide, and cisplatin (BEP) Â 1 dose, and actinomycin D, cyclophosphamide, and etoposide (ACE) Â 1 dose. mononuclear cytotrophoblasts stained positive for cytokeratin 7 and cytokeratin AE1/AE3. Fluorescence in-situ hybridization testing for isochromosome 12p was negative. Although 82% of cells had additional copies of chromosome 12, this was deemed to be a nonspecific result that is also found in tumors of nonegerm-cell origin. 10, 12 Immunoreactivity for GATA-3 provided evidence hinting at a urothelial origin of the tumor. Accordingly, the tumor was deemed to represent a urothelial carcinoma with prominent choriocarcinomatous differentiation. This was further supported by the presence on bladder biopsy of a high-grade noninvasive papillary urothelial carcinoma (stage Ta). Molecular analysis of a 50-gene panel using a Clinical Laboratory Improvement Amendmentsecertified next generation sequencing platform (Table 1) revealed only a single mutation in the codon 271, exon 8 (GAG to AAG) of the TP53 gene, that changed the encoded amino acid from glutamate to lysine (c.811G > A, p.E271K). This mutation was present at a low (< 10%) allelic frequency. A relatively common germ-line polymorphism was also noted in codon 541, exon 10 (ATG to CTG) of the KIT gene, that would change the encoded amino acid from methionine to leucine (c.1621A > C, p.M541L). Subsequent scrotal ultrasound on July 19, 2013, was negative for any testicular mass. At this time our patient's postnephrectomy serum b-hCG was 5277 mIU/mL, and his a-fetoprotein levels were 1.7 ng/ mL. His lactate dehydrogenase was not elevated. Ten days later, his bhCG had more than doubled to 11,474 mIU/mL. His creatinine levels were 1.63 mg/dL with an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 by the Modification of Diet in Renal Disease method. Magnetic resonance imaging of the brain with and without intravenous contrast on July 31, 2013, was negative for intracranial metastases. Given the aggressiveness of the tumor, we decided to quickly initiate chemotherapy using a regimen with a relatively low risk for nephrotoxicity and thrombocytopenia/bleeding that would be active against both choriocarcinoma and urothelial carcinoma. We accordingly initiated weekly intravenous (I. Because of a progressive decline in absolute neutrophil count, this cycle was provided with pegfilgrastim support. The patient also developed shingles at the T10 dermatome, which was treated with a 7-day course of valacyclovir 1 g every 12 hours followed by 500 mg daily. By August 27, 2013, the patient's creatinine had steadily increased to 1.77 md/dL. Subsequently, his regimen was switched on that day to I.V. gemcitabine 900 mg/m Remission of Urothelial Carcinoma developed severe peripheral neuropathy that precluded further administration of this regimen. We therefore again decided to switch therapy to actinomycin D, cyclophosphamide, and etoposide followed by cisplatin, vincristine, methotrexate, and bleomycin (POMB/ACE), given a prior report of efficacy with this regimen in male upper urinary tract choriocarcinoma. 6 Accordingly, on CT imaging, however, showed interval increase in the number and sizes of the pulmonary nodules, which was concerning for progressive pulmonary metastases when compared with prior imaging studies (July 2, 2013). We decided not to proceed with POMB and instead perform a biopsy of the lung nodules on November 13, 2013, to determine if there was any remaining urothelial or teratomatous component. Biopsy results revealed extensive necrosis without any viable tumor present. The patient was subsequently followed closely with CT imaging and serum markers every 3 months. His b-hCG has remained negative since that time. His lung nodules also remained relatively stable, although 6 lesions on the left lung demonstrated a mild, but concerning, increase in size over time. Therefore, on June 8, 2015, left thoracotomy with wedge resection of these 6 nodules along with mediastinal dissection of a level 9 L lymph node was performed. No viable tumor was present in any of the resected tissue. A cystoscopy on January 13, 2016, was negative for any tumor. The patient has recovered from his peripheral neuropathy and has remained free of disease to the time of this writing.
Discussion
On the basis of the small number of case reports available in the literature, the majority of primary choriocarcinomas of the upper urinary tract appear to have originated from trophoblastic differentiation of urothelial cells. 4, [7] [8] [9] [10] One study found that 9 of 47 highgrade urothelial neoplasms expressed hCG on immunohistochemistry, and 2 of these tumors demonstrated trophoblastic-like differentiation. 9 Alternatively, choriocarcinomas may originate from multipotent embryonal cells that became arrested during migration in ectopic locations. However, the majority of such extragonadal germ-cell tumors arise from midline structures anywhere between the level of the pineal gland to the coccyx. 13, 14 Extragonadal choriocarcinomas may also be metastases from a primary testicular origin that has spontaneously regressed. However, renal metastasis of testicular choriocarcinomas is extremely rare.
In the present case, the absence of isochromosome 12p (a specific marker of germ-cell tumors 15 ), positive immunoreactivity for GATA-3 (a relatively specific marker for urothelial carcinoma 16 ), and presence of a concurrent stage Ta high-grade noninvasive papillary urothelial carcinoma of the bladder (suggestive of field cancerization or seeding of cancer cells 17 ) all pointed toward a diagnosis of urothelial carcinoma with choriocarcinomatous differentiation. Ideally, such tumors should be treated with chemotherapy before nephroureterectomy, similar to other high-grade upper tract urothelial malignancies 18 and to choriocarcinoma in women. 19 However, because these tumors clinically mimic the more common renal-cell carcinoma, preoperative b-hCG levels will most often not be available, the diagnosis will be established after nephroureterectomy, and chemotherapy will be provided after surgery.
Conclusion
The present case posed a therapeutic dilemma because of our patient's compromised renal function after his nephroureterectomy. Given the aggressiveness and likely urothelial origin of choriocarcinomas of the upper urinary tract, nephron-sparing regimens, such as ATP and GTA, that are active against both choriocarcinoma and urothelial carcinoma can be effectively used. Given the high risk of relapse of choriocarcinomas with persisting serum b-hCG, this marker must become undetectable to ensure a cure. We were able to achieve this effect and thus produce a prolonged remission by consolidation with BEP followed by ACE.
